Kala Pharmaceuticals to Present at Two Upcoming Investor Conferences in September

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY mucus-penetrating particle (MPP) Drug Delivery Technology, today announced that members of its management team will participate in the following upcoming conferences in September:

2019 Wells Fargo Healthcare Conference
Date: Thursday, September 5, 2019
Fireside Chat Time: 8:00 a.m.
Location: Boston, MA

H.C. Wainwright 21^st Annual Global Investment Conference
Date: Tuesday, September 10, 2019
Presentation Time: 10:50 a.m.
Location: New York, NY

To access a live webcast and subsequent archived recording of the presentations, please visit the “Investors & Media” section on the Kala website at http://kalarx.com

About Kala Pharmaceuticals, Inc.

Kala is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY mucus-penetrating particle (MPP) Drug Delivery Technology, with an initial focus on the treatment of eye diseases. Kala has applied the AMPPLIFY Drug Delivery Technology to a corticosteroid, loteprednol etabonate (LE), designed for ocular applications, resulting in the August 2018 FDA approval of INVELTYS for the treatment of inflammation and pain following ocular surgery and its lead product candidate, KPI-121 0.25%, for the temporary relief of the signs and symptoms of dry eye disease.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190829005004/en/